Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Randomized, Double-blind Study Of The Efficacy And Safety Of 2 Doses Of Cp-690,550 Compared To Methotrexate In Methotrexate Navie Patients With Rheumatoid Arthritis

NCT01039688 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01039688
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01039688 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Randomized, Double-blind Study Of The Efficacy And Safety Of 2 Doses Of Cp-690,550 Compared To Methotrexate In Methotrexate Navie Patients With Rheumatoid Arthritis
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2010
Completion date
March 31, 2013
Enrollment
956 (actual)
Sites
176

Conditions

As the registry lists them; a condition with its own page is linked.

arthritis, rheumatoid